

Chicago Specials

Fall Group Meeting

OCTOBER 8 - 10, 2026



Genitourinary Committee

Genitourinary Committee

Leadership

Chair: Seth P. Lerner, MD
 Vice-Chair: Daniel P. Petrylak, MD
 Chair Emeritus: Ian M. Thompson, Jr., MD
 Executive Officer: Neeraj Agarwal, MD
 Statisticians: Cathy M. Tangen, DrPH
 Melissa Plets, MS
 Sam Callis, MS
 Gabby Lopez, MS
 Sara Threlkel, BS

Scientific Leadership

Bladder Organ Site Chairs: Siamak Daneshmand, MD (Localized)
 Thomas W. Flaig, MD (Advanced)
 Prostate Organ Site Chairs: Daniel W. Lin, MD (Localized)
 Tanya B. Dorff, MD (Advanced)
 Renal Organ Site Chairs: Brian Shuch, MD (Localized)
 Ulka N. Vaishampayan, MD (Advanced)
 Translational Medicine: Joshua J. Meeks, MD, PhD (GU Chair)
 Roger Li, MD (Bladder)
 Amir Goldkorn, MD (Prostate)
 David A. Braun, MD, PhD (Renal)
 Special Advisor: David J. McConkey, PhD
 Radiation Oncology: James B. Yu, MD
 Daniel A. Hamstra, MD
 Imaging: Evan Y. Yu, MD
 Immunotherapeutics: Shuchi Gulati, MD (Medical Onc)
 Pathology: M. Scott Lucia, MD
 Surgery: Kelly L. Stratton, MD
 Early Therapeutics: Parminder Singh, MD

Designates

Cancer Control: Clara Hwang, MD
 Sarah P. Psutka, MD, MSC
 Accrual Champion: Jessica D. McDermott, MD
 NCORP: Scott Edward Delacroix, Jr., MD
 Helen Heng-Shan Moon, MD
 Veterans Affairs: Michael M. Goodman, MD
 Aihua Edward Yen, MD
 International Liaison: Sumanta "Monty" Pal, MD
 Data Coordinators: Laura Wells, BA
 Tonya Johnson, BS
 Michele Counts, BS
 Oncology Research Professionals: Abigail L. Cornette, MS
 Gary Lee Duvall, RN

Patient Advocates: Darrell Nakagawa (Bladder)
 Joël R. Pointon, MPH (Prostate)
 Laura B. Esfeller, MA (Renal)
 Pharmaceutical Science: Catherine Chen, PharmD
 Sr. Protocol Project Manager: Megan Keim
 Clinical Trials Program Manager: Sarah Cantu

Time/Location

Saturday, October 10, 2026 9:15 a.m. - 11:15 a.m.

Room: Regency A (Ballroom Level)

Agenda

9:15 - 9:30 am: Chair's Welcome and Opening Remarks - Seth Lerner
 9:30 - 9:55 am: Cancer Control - Clara Hwang and Sarah Psutka
 9:55 - 11:15 am: Review of open approved trials - all organ site chairs
 Bladder – Sia Daneshmand and Tom Flaig
 Prostate – Tanya Dorff and Daniel Lin
 Renal – Brian Shuch and Ulka Vaishampayan

Cancer Control

Organ Site Chairs: Drs. Clara Hwang and Dr. Sarah Psutka

Active Studies

S1931 (Companion Study): Examining Psychosocial and Emotional Issues for Metastatic Kidney Cancer. PI: Cristiane Bergerot.

S1937 (Companion Study): Assessment of Quality of Life for S1937: A Phase III Randomized Trial of Eribulin with or without Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy. QoL Study Chair: Dr. Afsaneh Barzi. On hold until accrual picks up on S1937.

Bladder

Organ Site Chairs: Dr. Thomas Flaig (Advanced) and Dr. Siamak Daneshmand (Local).

Priority Study

S2427, "Bladder preservation with chemoradiotherapy or immunoradiotherapy after a good response to neoadjuvant chemotherapy in patients with muscle invasive bladder cancer

Genitourinary Committee

(BRIGHT)." Dr. L. Ballas. Activated 9/4/2025. Revision #1 released 1/15/2026.

Concepts in Development

S2611, "A Randomized Comparison of Intravesical TherapieS (ARCIS): A randomized phase III study of intravesical gemcitabine and docetaxel (GEM-DOCE) versus intravesical cretostimogene grenadenorepvec and gemcitabine (CRETO-GEM) for the treatment of bacille Calmette-Guérin (BCG)-unresponsive and BCG-exposed non-muscle invasive bladder cancer (NMIBC)." Dr. M. Tyson. GU Steering Committee approved 6/15/2026. Protocol is currently in development.

Active Studies

CTSU/A031701, "A Phase II Study of Dose-Dense Gemcitabine Plus Cisplatin (ddGC) in Patients with Muscle-Invasive Bladder Cancer with Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations." Drs. A. Gupta and S. Gupta. Activated: 8/1/18.

CTSU/A031803, "Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer." Drs. D. Tyson and C. Ramamurthy. Activated: 1/6/20. Closed to accrual: 7/23/2025.

CTSU/EA8185, "Phase II Study of Bladder-Sparing Chemoradiation with MEDI4736 (Durvalumab) in Clinical Stage III, Node Positive Bladder Cancer (INSPIRE)." Drs. T. Mitin and J. Meeks. Activated: 8/25/20. Closed to accrual: 10/2/2023.

CTSU/EA8192, "A Phase II/III Trial of MED14736 (Durvalumab) and Chemotherapy for Patients with High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy" Drs. S. Psutka and A. Tripathi. Activated: 5/6/21. Arm C Closed to Accrual as of 04/25/2025.

Closed Studies

S1011, "A Phase III Surgical Trial to Evaluate the Benefit of a Standard Versus an Extended Pelvic Lymphadenectomy Performed at Time of Radical Cystectomy for Muscle Invasive Urothelial Cancer." Drs. S. Lerner, A. Alva, and T. Koppie, et al. Activated: 8/1/11; Permanently Closed: 4/15/17. Listed as FDAAA/IRB Completed on 1/8/25.

S1602, "A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG Naïve High-Grade Non-Muscle Invasive Bladder Cancer." Drs. R. Svatek, A. Alva, and S. Lerner. Activated: 2/7/17; Permanently Closed: 12/15/2020.

S1605, "Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer." Drs. P. Black, P. Singh, and S. Lerner. Activated: 2/7/17; Permanently Closed: 7/5/19. FDAAA/IRB Completed.

S2011, "Randomized Phase II Trial of Gemcitabine, Avelumab, and Carboplatin vs. No Neoadjuvant Therapy Preceding Surgery for Cisplatin Ineligible Muscle-Invasive Urothelial Carcinoma." Drs. Sonpavde, M. Liss, and S. Lerner, et al. Activated: 10/6/21. Closed to Accrual: 11/15/23. Administratively Complete.

S1806, "Phase III Randomized Trial of Concurrent Chemoradiotherapy with or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer." Drs. P. Singh, S. Lerner, J. Efstathiou, et al. Activated: 4/19/19. Step 1 accrual closed 3/1/24. Revision #10 released 8/15/2025. Closed to accrual and treatment: 4/1/2024.

S1937, "A Phase III Trial of Eribulin (NSC #707389) with or Without Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy." Drs. S. Sadeghi and P. Lara. Activated: 2/16/21. Temporary Closure: 5/30/23. Re-opened Arms 1&3 to accrual and permanently closed Arm 2 on 2/15/24. Revision #4 had Sacituzumab govitecan removed as a treatment option on 2/3/25. Study closed to accrual 3/13/2026.

Prostate

Organ Site Chairs: Dr. Tonya Dorff (Advanced) and Dr. Daniel W. Lin (Local).

Priority Study

S2210, "Targeted neoadjuvant treatment for patients with localized prostate cancer and germline DNA repair deficiency." Dr. H. Cheng. Activated 8/14/23.

Concepts in Development

S2613, "Assessing the Need for Pelvic Lymphadenectomy at the Time of Prostatectomy for Prostate Cancer with PSMA-PET Based Evaluation: a Multicenter, Randomized Phase III Clinical Trial." Drs. Udit Singhal and Todd Morgan. GU Steering Committee approved 7/17/2026. Protocol is currently in development.

Active Studies

S2312, "A Phase III Study of Cabazitaxel with or without Carboplatin in Patients with metastatic castrate-resistant prostate cancer (mCRPC), Stratified by Aggressive Variant Signature." Dr. Paul Corn. Activated 9/3/24. Revision #1 released 1/15/2026.

Genitourinary Committee

S1802, "Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer." Drs. B. Chapin, A. Aparicio, and R. Valicenti. Activated: 9/17/18. Revision #5 released 8/15/24.

CTSU/A031102, "A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors." Dr. D. Quinn. Activated: 7/1/15. Closed to Accrual 10/26/2022.

CTSU/EA8171, "Multiparametric MRI (mpMRI) for Preoperative Staging and Treatment Planning for Newly-Diagnosed Prostate Cancer." Dr. M. Liss. Activated: 7/9/18. Closed to Accrual 2/28/2025.

CTSU/EA8184, "A Phase II Randomized Double Blinded Study of Green Tea Catechins (GTC) vs. Placebo in Men on Active Surveillance for Prostate Cancer: Modulation of Biological and Clinical Intermediate Biomarkers." Dr. R. Kopp. Activated: 5/10/21. Closed to Accrual 6/26/2025.

CTSU/EA8191, "Phase III Study of Local or Systemic Therapy Intensification Directed by PET in Prostate Cancer Patients with Post-Prostatectomy Biochemical Recurrence (INDICATE)." Dr. N. Vapiwala. Activated: 10/8/202. Arms A & B Closed to Accrual 1/31/2025.

CTSU/NRG-GU002, "Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy with or Without Adjuvant Docetaxel." Dr. D. Raben. Activated: 12/30/16. Closed to Accrual 9/6/2022.

CTSU/NRG-GU008, "Randomized Phase III Trial Incorporating Abiraterone Acetate with Prednisone and Apalutamide and Advanced Imaging into Salvage Treatment for Patients with Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE*) *Intensifying Treatment for Node Positive Prostate Cancer by Varying the Hormonal Therapy." Dr. D. Lin. Activated: 3/5/20; Temporarily Closed: 6/24/21; Re-activated: 12/1/21.

CTSU/NRG-GU009, "Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (PREDICT-RT*)." Dr. S. Zhang. Activated: 10/15/20; Temporarily Closed: 6/24/21; Re-activated: 12/15/21. Closed to Accrual 8/18/2025.

CTSU/NRGGU010, "Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification And Intensification Clinical Trial Evaluation (GUIDANCE)."

Drs. N Desai and A. Berlin. Activated: 11/3/2021. Groups 3 and 4 Closed to Accrual 11/22/2024.

CTSU/NRGGU011, "A Phase II Double-Blinded, Placebo-Controlled Trial of PROstate OligoMETastatic RadiotHERapy with or Without ANDrogen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG Promethean)." Dr. B. Koontz.

Closed Studies

S1216, "A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer." Drs. N. Agarwal, A. Goldkorn, S. Gupta, et al. Activated: 3/6/13; Permanently Closed: 7/15/17. All participants off of treatment and follow up by 7/15/25. FDAAA/IRB Completed.

CTSU/NRG-GU005, "Phase III IGRT and SBRT Vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer." Dr. A. Solanki. Activated: 11/16/17; Closed to accrual: 6/8/22. Closed to Accrual and Treatment 6/8/2022.

CTSU/NRG-GU006, "A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy with or Without Enhanced Anti-Androgen Therapy with Apalutamide in Recurrent Prostate Cancer." Dr. J. Zeng. Activated: 4/27/18; Permanently Closed: 5/19/20.

CTSU/RT0G-0924, "Androgen Deprivation Therapy and High Dose Radiotherapy with or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial. Dr. T. Marshall. Activated: 7/7/11; Permanently Closed: 6/24/19.

CTSU/NRG-GU007, "Randomized Phase II Trial of Niraparib with Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (with Initial Phase I) (NADIR*) *Randomized Phase II Trial of Niraparib With Standard Combination Androgen Deprivation Therapy (ADT) and Radiotherapy In High Risk Prostate Cancer (With Initial Phase I)." Dr. D. VanderWeele. Activated: 6/3/19; Temporarily Closed: 5/5/21; Reactivated of dose level 2 (phase I) for 1 additional patient: 9/14/21; Temporarily closed to accrual for phase I dose level 2: 11/4/21; Re-activated to accrual for phase I/dose level 3: 12/6/21; Temporarily Closed: 7/11/2022.

CTSU/EA8153, "Cabazitaxel with Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHARTED2 Trial." Dr. P. Corn. Activated: 2/8/18; Permanently Closed: 4/2/21; Tobacco use assessment sub-study permanently closed: 10/8/21.

Genitourinary Committee

CTSU/AGCT1531, "A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors." Dr. A. D'Souza. Activated: 5/8/17; PRO study Temporarily Closed: 2/12/21. Stratum 2 Temporarily Closed to Accrual as of 12/17/2024. AYA-HEARS Ototoxicity PRO Study Temporarily Closed to Accrual as of 02/12/2021.

Renal

Organ Site Chairs: Dr. Ulka Vaishampayan (Advanced) and Dr. Brian Shuch (Local).

Priority Study

S1931, "Phase III Trial of Immunotherapy-Based Combination Therapy with or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (PROBE Trial)." Drs. H. Kim and U. Vaishampayan. Activated: 11/16/20. Revision #10 released on 2/2/2026.

Active Studies

CTSU/AREN1721, "A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups." Dr. M. Parikh. Activated: 10/9/18; Temporarily Closed: 3/24/21; Re-activated: 2/7/22. Closed to Accrual 03/24/2023.

CTSU/A031704, "PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer [PDIGREE]." Dr. T. Zhang. Activated: 5/9/19; Step 1 temporarily closed: 3/8/21; Step 1 re-activated: 3/26/21. Closed to Accrual 5/15/2024.

CTSU/A031801, "A Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients with Advanced Renal Cell Carcinoma with Bone Metastasis (Radical)." Dr. M. Parikh. Activated: 12/13/19. Closed to Accrual 12/19/2025.

CTSU/A031901, "Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: A randomized Phase 3 non-Inferiority Trial." Dr. D. Vaena. Activated: 12/10/20. Closed to Accrual 11/29/2022.

S2419, "Phase III Double Blinded Trial of Immune-Based Therapy with a Live Biotherapeutic CBM588, or Placebo for Frontline Therapy of Advanced Clear Cell Renal Cell Carcinoma [BioFront Trial]." Drs. P. Barata and U. Vaishampayan. Activated 4/22/2026.

Closed Studies

S1500, "A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)." Drs. S. Pal and P. Lara. Activated 4/5/16; Permanently Closed: 12/15/19.

S0931, "EVEREST: Everolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study." Drs. C. Ryan, E. Heath, P. Lara, et al. Activated: 4/1/11; Permanently Closed: 9/15/16.

S2200, "A Phase II Randomized Trial of Cabozantinib (NSC #761968) with or without Atezolizumab (NSC #783608) in Patients with Advanced Papillary Renal Cell Carcinoma (PAPMET2)." Drs. B. Maughan and S. Pal. Activated 9/19/22. Temporarily closed to accrual 1/17/2026. Permanently Closed: 3/1/2026.

CTSU/E2810, "Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients with Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy." Dr. S. Pal. Activated: 8/8/12; Permanently closed: 7/25/17.

CTSU/A031501, "Phase III Randomized Adjuvant study of Pembrolizumab in Muscle Invasive and Locally Advanced Urothelial Carcinoma (AMBASSADOR) Versus Observation." Dr. G. Sonpavde. Activated: 9/21/17; Permanently Closed: 8/24/21.

CTSU/EA8143, "A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)." Drs. P. Lara and B. Shuch. Activated: 2/2/17; Permanently Closed: 6/9/21.

Translational Medicine

Chair: Dr. Joshua Meeks

Bladder Chair: Dr. Roger Li

Prostate Chair: Dr. Amir Goldkorn

Renal Chair: Dr. David Braun

Diverse Studies of Interest

S1609, "DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors." Drs. S. Patel, Y. Chae, R. Kurzrock, et al. Activated: 1/13/17; Permanently Closed: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 13, 14, 15, 16, 17, 18, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 39, 41, 42, 43, 44, 45, 48, 51, 52, and 53; Temporarily Closed: 38, 40, 46, and 51. Closed to Accrual 3/15/2023.

Genitourinary Committee

CTSU/A031702, “A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)” Dr. S. Liu. Activated: 4/12/19; Open Cohorts: A, C, D, J, H, L. Temporarily Closed Cohorts: B, E, F, G, I K.

CTSU/EAY 131, “Molecular Analysis for Therapy Choice (MATCH).” Dr. V. Villalobos. Activated: 8/12/15; Closed to Accrual 12/23/2022.

CTSU/EA8134, “InPACT- International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study).” Dr. C. Pettaway. Activated: 9/8/17.

Publications

The publication papers listed below from 2026 have not appeared as published in previous Group Meeting publications listings. Accepted and submitted manuscripts are also listed, with the journal names withheld to honor journal embargo policies. Conference abstracts are not included.

Published/Accepted Manuscripts

S1314 Proliferation- and cytotoxic immune signatures identify chemotherapy-responsive bladder tumors in a molecular subtype dependent manner. Zadoroznyj A, Eriksson P, Bernardo C, Tran L, Mattsson CA, Flaig T, Tangen C, Lerner S, McConkey D, Hoglund M, Leidberg F, Sjodahl G. *NPJ Precision Oncology*. 2026.
<https://pubmed.ncbi.nlm.nih.gov/42399473/>

S1806 INTACT (SWOG/NRG S1806) Phase III randomized trial of concurrent Chemoradiotherapy with or without Atezolizumab in localized muscle invasive bladder cancer. Trial design, eligibility criteria, patient enrollment characteristics and central review of clinical stageSingh P, Plets M, Efsthathiou J, Jhavar SG, Tangen CM, Delacroix Jr S, Marquette C, Khalil MF, Scher K, Sachdev S, Johnson III BA, Jani A, Cross B, Grivas P, Palopoli J, Kirchner A, Shen X, Parikh M, Olson A, Mehan P, Feng F, Costello B, Joshi M, Daneshmand S, Petrylak D, Thompson I, Nguyen PL, Lerner SP. Accepted 2026.

Submitted Manuscripts

S1216 Inherited variants in SRD5A genes and response to hormonal therapy in prostate cancer (SWOG S1216). Ingles S, Pinski J, Manojlovic Z, Xiong S, Weisenberger D, Goldkorn A, Tangen C, McConkey D, Lara P, Hussain M, Quinn D, Thompson I, Lerner S, Dorff T, Agarwal N. Submitted 2025.

S9346 Evaluating Survival Post-7-Month PSA Response, Stratified by Response, Disease Extent, and Intermittent vs. Continuous ADT in Metastatic Hormone-Sensitive Prostate Cancer: The S9346 Trial. Sokolova A, Tangen C, Hussain M, Sweeney C, Dorff T, Ong M, Swami U, Aggarwal N, Thompson I, Lerner S. Submitted.

Multiple Studies Practice Patterns in Metastatic Hormone-Sensitive Prostate Cancer: A Survey of North American Cooperative Group Oncologists. Breen P, Chalker C, Ong M, Anya O, McKay R, Carducci M, Kyriakopoulos C, Schweizer M, Haas N, Mandl A, Tangen C, Gulati S, Keim M, Lerner S, Ryan C, Ng R, Dorff T, Sokolova A. Submitted.

S1602 A Phase III Randomized Trial to Evaluate BCG Strain Differences and Priming for Bladder Cancer. Svatek RS, Tangen C, Meeks JJ, Gilbert SM, Lotan Y, Tyson M, Crispen P, Delacroix SE, Gills J, Daneshmand S, Woods M, Master VA, Mark JR, Alva ASA, Bangs R, Nakagawa D, Unger JM, Plets M, Thompson Jr IM, Lerner SP. Submitted 2026.

[illegible]

Genitourinary Committee

Accrual from trials that are open as of 6/30/2026 or have closed in the prior 18 months, by Institution and Study

	<i>S1802</i>	<i>S1931</i>	<i>S1937</i>	<i>S2200</i>	<i>S2210</i>	<i>S2312</i>	<i>S2419</i>	<i>S2427</i>	<i>A021804</i>	<i>A031701</i>
Northwestern University LAPS	-	1	1	1	-	3	-	1	-	-
Ohio St University Comprehensive Cancer Center LAPS	2	-	-	-	-	-	-	-	-	-
Oregon Health and Science University	-	3	3	1	1	1	-	-	1	-
Regents of the University of Michigan	2	27	4	-	-	-	-	-	-	-
Rhode Island Hospital	-	-	-	-	-	-	-	-	-	-
Southeast Clinical Oncology Research Consor NCORP	9	-	-	-	-	3	-	-	-	-
Sutter Cancer Research Consortium	-	-	-	-	-	-	-	-	-	-
The Hawaii NCORP	-	-	-	-	-	-	-	-	-	-
NCI Comm Oncology Research Prgrm: New Mex NCORP	-	2	1	-	-	-	-	-	-	-
The U of Kansas Cancer Centers- MCA Rural NCORP	7	-	4	-	-	-	-	-	-	-
The West Clinic - Wolf River	-	-	5	-	-	-	-	-	-	-
Tulane University School of Medicine	-	9	-	-	-	-	-	-	-	-
UC Irvine Health/Chao Family Comp Cancer Center	11	1	4	-	-	1	-	-	-	-
UC San Diego Moores Cancer Center	8	-	-	-	-	-	-	-	-	-
UCLA / Jonsson Comprehensive Cancer Center	-	4	-	-	-	-	-	-	-	-
UPMC Hillman Cancer Center LAPS	-	4	2	-	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	10	2	17	-	-	-	-	1	-	-
U of Alabama at Birm/Deep S Research Consort LAPS	-	7	-	-	-	-	-	3	-	-
University of Arizona LAPS	7	3	-	-	-	-	-	-	-	-
University of Arkansas for Medical Sciences	11	-	-	1	-	2	-	-	-	-
U of California Davis Comprehensive Cancer Center	18	5	6	-	-	-	-	-	-	11
University of Cincinnati Cancer Center-UC Medical Cntr	8	3	-	-	-	-	-	-	-	-
University of Colorado Cancer Center LAPS	10	-	10	-	-	-	-	-	-	-
University of Kentucky/Markey Cancer Center	2	-	1	-	-	-	-	-	-	-
University of Mississippi Medical Center	1	-	1	1	-	-	-	-	-	-
University of Nebraska Medical Center	10	-	-	-	-	2	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	47	6	8	3	-	5	-	1	-	-
University of Rochester LAPS	26	4	-	-	-	-	-	-	-	2
University of Texas Health Science Center at San Antonio	2	7	-	-	-	1	-	-	-	-
University of Texas MD Anderson Cancer Center LAPS	92	-	-	-	-	18	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	20	2	4	4	-	-	-	-	-	-
Upstate Carolina Consort Comm Oncology Res Prgrm	3	-	-	-	-	-	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	9	-	-	-	-	-	-	-	-	-
Virginia Mason Medical Center	-	-	-	-	-	-	-	-	-	-
Wayne State University/Karmanos Cancer Institute	1	-	-	-	-	-	-	-	-	-
Western States Cancer Research NCORP	-	-	-	-	-	-	-	-	-	-
Wisconsin NCI Community Oncology Research Program	16	1	1	-	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	1	-	4	-	-	2	-	-	-	-
ALLIANCE	125	9	7	2	-	12	-	5	-	-
ECOG-ACRIN	111	17	22	6	-	5	-	5	-	-
NRG	129	16	3	4	-	-	-	2	-	-
Total	1,039	154	132	36	6	64	2	22	1	28

[illegible]

Genitourinary Committee

Accrual from trials that are open as of 6/30/2026 or have closed in the prior 18 months, by Institution and Study

	A031702	A031801	A031803	A032102	A032103	A032201	A032302	A032303	A032304	CCTG-PR24
Northwestern University LAPS	-	-	-	-	-	-	-	-	-	-
Ohio St University Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-	-	-	-
Oregon Health and Science University	6	-	-	-	7	6	-	-	-	-
Regents of the University of Michigan	-	-	-	-	4	-	-	-	-	-
Rhode Island Hospital	-	-	-	-	-	-	-	-	-	-
Southeast Clinical Oncology Research Consor NCORP	-	-	-	-	-	-	-	-	-	-
Sutter Cancer Research Consortium	-	-	-	-	-	-	-	-	-	-
The Hawaii NCORP	-	-	-	-	-	-	-	-	-	-
NCI Comm Oncology Research Prgrm: New Mex NCORP	-	-	-	-	-	-	-	-	-	-
The U of Kansas Cancer Centers- MCA Rural NCORP	1	-	-	-	-	-	-	-	-	-
The West Clinic - Wolf River	-	-	-	-	-	-	-	-	-	-
Tulane University School of Medicine	-	-	-	-	-	-	-	-	-	-
UC Irvine Health/Chao Family Comp Cancer Center	-	-	-	-	-	3	-	-	1	-
UC San Diego Moores Cancer Center	-	-	-	-	-	-	-	-	-	-
UCLA / Jonsson Comprehensive Cancer Center	-	-	-	-	-	-	-	-	-	-
UPMC Hillman Cancer Center LAPS	-	-	-	-	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	5	-	-	-	-	-	-	-	-	-
U of Alabama at Birm/Deep S Research Consort LAPS	1	1	12	-	-	-	-	2	-	-
University of Arizona LAPS	-	-	-	-	3	3	3	-	-	-
University of Arkansas for Medical Sciences	-	-	-	-	1	-	-	-	-	-
U of California Davis Comprehensive Cancer Center	-	7	5	3	3	1	-	-	-	-
University of Cincinnati Cancer Center-UC Medical Cntr	-	-	-	-	1	-	-	-	-	-
University of Colorado Cancer Center LAPS	-	-	-	-	-	1	-	-	-	-
University of Kentucky/Markey Cancer Center	-	-	-	-	3	-	-	-	-	-
University of Mississippi Medical Center	1	-	-	-	2	-	-	-	-	-
University of Nebraska Medical Center	-	-	-	-	2	-	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	-	-	-	-	1	-	-	-	-	-
University of Rochester LAPS	3	-	-	-	5	-	-	-	-	-
University of Texas Health Science Center at San Antonio	-	-	6	-	-	-	-	-	-	-
University of Texas MD Anderson Cancer Center LAPS	-	-	-	-	-	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	6	-	-	-	-	-	-	-	-
Upstate Carolina Consort Comm Oncology Res Prgrm	-	-	-	-	-	-	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	-	-	-	-	-	-	-	-	-
Virginia Mason Medical Center	-	-	-	-	1	-	-	-	-	-
Wayne State University/Karmanos Cancer Institute	-	-	-	-	1	-	-	-	-	-
Western States Cancer Research NCORP	-	-	-	-	-	-	-	-	-	-
Wisconsin NCI Community Oncology Research Program	-	-	-	-	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	-	-	-	-	-	-	-	-
ALLIANCE	-	-	-	-	-	-	-	-	-	-
ECOG-ACRIN	-	-	-	-	-	-	-	-	-	-
NRG	-	-	-	-	-	-	-	-	-	-
Total	28	15	47	3	44	17	3	3	1	3

Genitourinary Committee

Accrual from trials that are open as of 6/30/2026 or have closed in the prior 18 months, by Institution and Study

	CCTG-PR26	EA8134	EA8171	EA8191	EA8192	EA8212	NRGGU008	NRGGU009	NRGGU010	NRGGU011
Arnot Ogden Medical Center/Falck Cancer Center	-	-	-	-	-	-	-	-	4	-
Audie L Murphy VA Hospital	-	-	49	-	-	-	-	-	-	-
Banner MD Anderson Cancer Center	-	-	-	-	-	26	-	1	3	-
Baylor College of Medicine/Comprehensive Cancer Cntr	-	-	-	-	-	29	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-	-	-	-
Cancer Research Consortium of West Michigan NCORP	-	-	-	-	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	-	-	-	-	-	-	-	-	-	-
Cancer Research of Wisconsin & N Michigan Consort	-	-	-	-	-	-	-	-	-	-
Carle Cancer Center NCI Comm Oncology Research Prgrm	-	-	-	-	-	-	-	-	-	-
Carolinas Medical Center/Levine Cancer Institute	-	-	-	-	-	-	-	1	-	-
Cedars-Sinai Medical Center	-	-	-	-	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	-	-	-	-	-	-	-	-	-	-
CommonSpirit Health Research Institute	-	-	-	-	-	-	-	-	-	-
Dayton NCI Community Oncology Research Program	-	-	-	-	-	-	-	-	-	-
Desert Regional Medical Center	-	-	-	-	-	-	-	-	-	-
Essentia Health NCI Comm Oncology Research Prgrm	-	-	-	-	-	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	-	33	-	16	-	-	-	7
Georgia CaRes	-	-	-	-	-	-	-	-	-	-
Georgia NCI Community Oncology Research Program	-	-	-	-	-	-	-	-	-	-
Grupo Oncologico Cooperativo de Investigacion	-	-	-	-	-	-	-	-	-	-
Gulf South Clinical Trials Network (Gulf South NCORP)	-	-	11	-	-	71	6	16	6	5
Hartford Hospital	-	-	-	-	-	-	-	-	-	-
Heartland Cancer Research NCORP	-	-	-	-	-	-	-	-	-	-
Henry Ford Hospital	-	-	1	-	-	-	-	-	-	-
Houston Methodist Hospital	-	-	-	-	-	2	-	-	-	-
Instituto Nacional De Cancerologia	-	-	-	-	-	-	-	-	-	-
Instituto Nacional De Cancerologia de Mexico	-	4	-	-	-	-	-	-	-	-
Intermountain Medical Center	-	-	-	-	-	-	-	-	3	-
Kaiser Permanente NCI Comm Oncology Research Prgrm	-	-	-	-	-	-	-	-	-	-
Lahey Clinic	-	-	-	-	-	-	-	-	-	-
Loyola University Medical Center	-	-	-	-	-	6	-	-	-	-
Malcom Randall Vets Administration Medical Center	-	-	-	-	-	-	-	-	-	-
Mass Vets Epidemiology Research & Information Center	-	-	-	-	-	-	-	-	-	-
Medical U of South Carolina NCORP Community Site	-	2	-	3	-	17	-	-	1	-
Michigan Cancer Research Consortium NCORP	-	-	-	-	-	-	-	-	-	-
Moffitt Cancer Center	-	-	-	-	-	-	-	-	-	-
Montana Cancer Consortium NCORP	-	-	-	-	-	-	-	2	-	-
Mount Sinai Braman Comprehensive Cancer Center	-	-	-	-	-	-	-	-	-	-
Mount Sinai Hospital	-	-	-	2	-	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	-	-	-	1	-	-	-	-
Nevada Cancer Research Foundation NCORP	-	-	-	-	-	-	-	-	-	-
Northwell Health NCORP	-	-	-	1	-	-	4	20	3	-

Genitourinary Committee

Accrual from trials that are open as of 6/30/2026 or have closed in the prior 18 months, by Institution and Study

	CCTG-PR26	EA8134	EA8171	EA8191	EA8192	EA8212	NRGGU008	NRGGU009	NRGGU010	NRGGU011
Northwestern University LAPS	-	-	-	-	-	-	-	-	4	-
Ohio St University Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-	-	-	-
Oregon Health and Science University	2	-	15	18	-	32	-	-	-	7
Regents of the University of Michigan	-	-	-	-	-	-	-	-	1	-
Rhode Island Hospital	-	-	-	-	-	-	-	1	-	-
Southeast Clinical Oncology Research Consor NCORP	-	-	-	-	-	-	-	-	-	-
Sutter Cancer Research Consortium	-	-	-	-	-	-	-	6	11	3
The Hawaii NCORP	-	-	2	-	-	-	-	-	-	-
NCI Comm Oncology Research Prgrm: New Mex NCORP	-	-	-	-	-	-	-	-	-	-
The U of Kansas Cancer Centers- MCA Rural NCORP	-	-	-	-	-	-	3	11	9	-
The West Clinic - Wolf River	-	-	-	-	-	-	-	-	-	-
Tulane University School of Medicine	-	-	-	-	-	-	-	-	-	-
UC Irvine Health/Chao Family Comp Cancer Center	-	-	-	-	-	-	3	-	-	-
UC San Diego Moores Cancer Center	-	-	-	1	1	5	-	2	2	-
UCLA / Jonsson Comprehensive Cancer Center	-	-	-	-	-	-	-	-	-	-
UPMC Hillman Cancer Center LAPS	-	-	-	-	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	17	-	-	-	20	-	-	-	-
U of Alabama at Birm/Deep S Research Consort LAPS	-	-	-	-	-	-	-	-	-	-
University of Arizona LAPS	-	-	-	-	-	-	-	1	-	-
University of Arkansas for Medical Sciences	-	3	-	-	-	-	-	-	-	-
U of California Davis Comprehensive Cancer Center	-	-	-	-	-	4	-	1	-	-
University of Cincinnati Cancer Center-UC Medical Cntr	-	-	-	-	-	-	-	-	-	-
University of Colorado Cancer Center LAPS	-	1	-	-	2	-	-	17	13	2
University of Kentucky/Markey Cancer Center	-	-	-	-	4	15	-	-	-	-
University of Mississippi Medical Center	-	-	-	-	-	-	-	2	-	-
University of Nebraska Medical Center	-	-	-	-	-	-	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	-	-	-	6	-	7	-	4	4	-
University of Rochester LAPS	-	-	-	-	-	-	-	-	-	-
University of Texas Health Science Center at San Antonio	-	-	13	2	-	-	-	-	-	-
University of Texas MD Anderson Cancer Center LAPS	-	-	-	-	-	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	-	-	-	-	-	-	-	-
Upstate Carolina Consort Comm Oncology Res Prgrm	-	-	-	-	-	-	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	-	-	-	-	-	-	-	-	-
Virginia Mason Medical Center	-	-	-	-	-	9	-	4	4	-
Wayne State University/Karmanos Cancer Institute	-	-	-	-	-	-	-	-	-	-
Western States Cancer Research NCORP	-	-	-	-	-	-	-	-	1	-
Wisconsin NCI Community Oncology Research Program	-	-	-	-	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	-	-	-	-	-	-	-	-
ALLIANCE	-	-	-	-	-	-	-	-	-	-
ECOG-ACRIN	-	-	-	-	-	-	-	-	-	-
NRG	-	-	-	-	-	-	-	-	-	-
Total	2	27	91	66	7	260	16	89	69	24

Genitourinary Committee

Accrual from trials that are open as of 6/30/2026 or have closed in the prior 18 months, by Institution and Study

	NRGGU012	NRGGU013
Arnot Ogden Medical Center/Falck Cancer Center	-	-
Audie L Murphy VA Hospital	-	-
Banner MD Anderson Cancer Center	-	-
Baylor College of Medicine/Comprehensive Cancer Cntr	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-
Cancer Research Consortium of West Michigan NCORP	-	-
Cancer Research for the Ozarks NCORP	-	-
Cancer Research of Wisconsin & N Michigan Consort	-	-
Carle Cancer Center NCI Comm Oncology Research Prgrm	-	-
Carolinas Medical Center/Levine Cancer Institute	-	-
Cedars-Sinai Medical Center	-	-
City of Hope Comprehensive Cancer Center	-	-
CommonSpirit Health Research Institute	-	-
Dayton NCI Community Oncology Research Program	-	-
Desert Regional Medical Center	-	-
Essentia Health NCI Comm Oncology Research Prgrm	-	1
Fred Hutchinson Cancer Research Center LAPS	-	10
Georgia CaRes	-	-
Georgia NCI Community Oncology Research Program	-	-
Grupo Oncologico Cooperativo de Investigacion	-	-
Gulf South Clinical Trials Network (Gulf South NCORP)	2	-
Hartford Hospital	-	-
Heartland Cancer Research NCORP	-	-
Henry Ford Hospital	-	-
Houston Methodist Hospital	-	-
Instituto Nacional De Cancerologia	-	-
Instituto Nacional De Cancerologia de Mexico	-	-
Intermountain Medical Center	-	-
Kaiser Permanente NCI Comm Oncology Research Prgrm	-	-
Lahey Clinic	-	-
Loyola University Medical Center	-	-
Malcom Randall Vets Administration Medical Center	-	-
Mass Vets Epidemiology Research & Information Center	-	3
Medical U of South Carolina NCORP Community Site	-	-
Michigan Cancer Research Consortium NCORP	-	-
Moffitt Cancer Center	-	-
Montana Cancer Consortium NCORP	-	-
Mount Sinai Braman Comprehensive Cancer Center	-	-
Mount Sinai Hospital	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-
Nevada Cancer Research Foundation NCORP	-	-
Northwell Health NCORP	-	-

Genitourinary Committee

Accrual from trials that are open as of 6/30/2026 or have closed in the prior 18 months, by Institution and Study

	NRGGU012	NRGGU013
Northwestern University LAPS	-	-
Ohio St University Comprehensive Cancer Center LAPS	-	-
Oregon Health and Science University	-	-
Regents of the University of Michigan	-	-
Rhode Island Hospital	-	-
Southeast Clinical Oncology Research Consor NCORP	-	-
Sutter Cancer Research Consortium	1	-
The Hawaii NCORP	-	-
NCI Comm Oncology Research Prgrm: New Mex NCORP	-	-
The U of Kansas Cancer Centers- MCA Rural NCORP	-	-
The West Clinic - Wolf River	-	-
Tulane University School of Medicine	-	-
UC Irvine Health/Chao Family Comp Cancer Center	-	-
UC San Diego Moores Cancer Center	3	-
UCLA / Jonsson Comprehensive Cancer Center	-	-
UPMC Hillman Cancer Center LAPS	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-
U of Alabama at Birm/Deep S Research Consort LAPS	-	-
University of Arizona LAPS	-	-
University of Arkansas for Medical Sciences	-	-
U of California Davis Comprehensive Cancer Center	-	-
University of Cincinnati Cancer Center-UC Medical Cntr	-	-
University of Colorado Cancer Center LAPS	-	-
University of Kentucky/Markey Cancer Center	-	-
University of Mississippi Medical Center	-	-
University of Nebraska Medical Center	2	-
University of Oklahoma Health Sciences Center LAPS	2	5
University of Rochester LAPS	-	-
University of Texas Health Science Center at San Antonio	-	-
University of Texas MD Anderson Cancer Center LAPS	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	-
Upstate Carolina Consort Comm Oncology Res Prgrm	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	-
Virginia Mason Medical Center	-	-
Wayne State University/Karmanos Cancer Institute	-	-
Western States Cancer Research NCORP	-	-
Wisconsin NCI Community Oncology Research Program	-	-
Yale University - Yale Cancer Center LAPS	-	-
ALLIANCE	-	-
ECOG-ACRIN	-	-
NRG	-	-
Total	10	19

